(Stroke. 1996;27:2136-2142.)
© 1996 American Heart Association, Inc.
Articles |
Use of a Global Test for Multiple Outcomes in Stroke Trials With Application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial
the Division of Biostatistics and Research Epidemiology, Henry Ford Health Sciences Center, Detroit, Mich (B.C.T., M.L.); Division of Stroke and Trauma, National Institute of Neurological Disorders and Stroke, Bethesda, Md (J.M.); Office of Biostatistics Research, National Heart, Lung, and Blood Institute, Bethesda, Md (N.L.G.); National Cancer Institute, Division of Cancer Prevention and Control, Bethesda, Md (J.L.); Department of Neurology, University of Cincinnati (Ohio) Medical Center (T.B.); Stroke Center, University of California at San Diego (P.L.); and the Department of Neurology, University of Texas at Houston Medical School (J.G.).
Background The National Institute of Neurological Disorders and Stroke (NINDS) held a workshop on statistical approaches to analysis of acute stroke trials that have multiple prespecified outcomes. An objective was to plan for statistical analysis of the NINDS t-PA Stroke Trial, a randomized, double-blind, placebo-controlled trial of recombinant tissue plasminogen activator (rt-PA) for patients with acute ischemic stroke. Treatment success was defined as a "consistent and persuasive difference" in the proportion of patients achieving favorable outcomes on the Barthel Index, Modified Rankin Scale, Glasgow Outcome Scale, and National Institutes of Health Stroke Scale. The Data and Safety Monitoring Committee for the trial recommended this outcome because the committee did not believe that a positive result for a single outcome would provide sufficient evidence of efficacy.
Summary of Comment Workshop participants accepted the global test as a viable approach to testing the primary trial hypothesis. Clinician participants advocated categorizing outcomes as favorable/unfavorable, outcomes more clinically meaningful than continuous outcomes for evaluating a drug with potentially serious side effects. They agreed that a global test was appropriate for ischemic stroke when no single outcome is accepted. Hypothetical, special-case examples illustrate that highly correlated outcomes diminish the power of the global test. NINDS t-PA Stroke Trial data demonstrate the clinical interpretability of the global test.
Conclusions Workshop participants concluded that a global statistic should be used to test the trial's primary hypothesis accompanied by secondary tests of individual outcomes. Workshop participants recommended familiarizing the clinical/scientific community with the global approach.
Key Words: cerebral ischemia • cerebrovascular disorders • clinical trials • data analysis, statistical
This article has been cited by other articles:
 |
|
 |
|
  C. R Gross, M. J. Kreitzer, M. Reilly-Spong, N. Y Winbush, E K. Schomaker, and W. Thomas Mindfulness meditation training to reduce symptom distress in transplant patients: rationale, design, and experience with a recycled waitlist Clinical Trials, February 1, 2009; 6(1): 76 - 89. [Abstract] [PDF]
|
|
|
|
 |
|
 W. Hacke, M. Kaste, E. Bluhmki, M. Brozman, A. Davalos, D. Guidetti, V. Larrue, K. R. Lees, Z. Medeghri, T. Machnig, et al. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke N. Engl. J. Med., September 25, 2008; 359(13): 1317 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lyden Thrombolytic Therapy for Acute Stroke -- Not a Moment to Lose N. Engl. J. Med., September 25, 2008; 359(13): 1393 - 1395. [Full Text] [PDF]
|
|
|
|
 |
|
 The IMS II Trial Investigators The Interventional Management of Stroke (IMS) II Study Stroke, July 1, 2007; 38(7): 2127 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Koziol and A. C. Feng On the Analysis and Interpretation of Outcome Measures in Stroke Clinical Trials: Lessons From the SAINT I Study of NXY-059 for Acute Ischemic Stroke Stroke, October 1, 2006; 37(10): 2644 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Kent, M. D. Hill, R. Ruthazer, S. B. Coutts, A. M. Demchuk, I. Dzialowski, O. Wunderlich, and R. von Kummer "Clinical-CT Mismatch" and the Response to Systemic Thrombolytic Therapy in Acute Ischemic Stroke Stroke, August 1, 2005; 36(8): 1695 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. L. Wilson, A. Hareendran, A. Hendry, J. Potter, I. Bone, and K. W. Muir Reliability of the Modified Rankin Scale Across Multiple Raters: Benefits of a Structured Interview Stroke, April 1, 2005; 36(4): 777 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Kent, L. L. Price, P. Ringleb, M. D. Hill, and H. P. Selker Sex-Based Differences in Response to Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Pooled Analysis of Randomized Clinical Trials Stroke, January 1, 2005; 36(1): 62 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gao, K. S. Wong, T. Hansberg, W. W. M. Lam, D. W. Droste, and E. B. Ringelstein Microembolic Signal Predicts Recurrent Cerebral Ischemic Events in Acute Stroke Patients With Middle Cerebral Artery Stenosis Stroke, December 1, 2004; 35(12): 2832 - 2836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Ingall, W. M. O'Fallon, K. Asplund, L. R. Goldfrank, V. S. Hertzberg, T. A. Louis, and T. J. H. Christianson Findings From the Reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial Stroke, October 1, 2004; 35(10): 2418 - 2424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Weir, M. Kaste, K. R. Lees, and for the Glycine Antagonist in Neuroprotection Int Targeting Neuroprotection Clinical Trials to Ischemic Stroke Patients With Potential to Benefit From Therapy Stroke, September 1, 2004; 35(9): 2111 - 2116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Kent, J. Hinchey, L. L. Price, S. R. Levine, and H. P. Selker In Acute Ischemic Stroke, Are Asymptomatic Intracranial Hemorrhages Clinically Innocuous? Stroke, May 1, 2004; 35(5): 1141 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The IMS Study Investigators Combined Intravenous and Intra-Arterial Recanalization for Acute Ischemic Stroke: The Interventional Management of Stroke Study Stroke, April 1, 2004; 35(4): 904 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. B. Young, K. R. Lees, and C. J. Weir Strengthening Acute Stroke Trials Through Optimal Use of Disability End Points Stroke, November 1, 2003; 34(11): 2676 - 2680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Hill, H. A. Rowley, F. Adler, M. Eliasziw, A. Furlan, R. T. Higashida, L. R. Wechsler, H. C. Roberts, W. P. Dillon, N. J. Fischbein, et al. Selection of Acute Ischemic Stroke Patients for Intra-Arterial Thrombolysis With Pro-Urokinase by Using ASPECTS Stroke, August 1, 2003; 34(8): 1925 - 1931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Higashida and A. J. Furlan Trial Design and Reporting Standards for Intra-Arterial Cerebral Thrombolysis for Acute Ischemic Stroke Stroke, August 1, 2003; 34 (8): e109 - e137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Kent, R. Ruthazer, and H. P. Selker Are Some Patients Likely to Benefit From Recombinant Tissue-Type Plasminogen Activator for Acute Ischemic Stroke Even Beyond 3 Hours From Symptom Onset? Stroke, February 1, 2003; 34(2): 464 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Tirschwell, W.T. Longstreth Jr, K. J. Becker, R. E. Gammans Sr, L. A. Sabounjian, S. Hamilton, and L. B. Morgenstern Shortening the NIH Stroke Scale for Use in the Prehospital Setting Stroke, December 1, 2002; 33(12): 2801 - 2806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Davalos, J. Castillo, J. Alvarez-Sabin, J. J. Secades, J. Mercadal, S. Lopez, E. Cobo, S. Warach, D. Sherman, W. M. Clark, et al. Oral Citicoline in Acute Ischemic Stroke: An Individual Patient Data Pooling Analysis of Clinical Trials Stroke, December 1, 2002; 33(12): 2850 - 2857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zhang, Y. Wang, L. Zhang, Z. Zhang, W. Tsang, M. Lu, L. Zhang, and M. Chopp Sildenafil (Viagra) Induces Neurogenesis and Promotes Functional Recovery After Stroke in Rats Stroke, November 1, 2002; 33(11): 2675 - 2680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Weimar, T. Kurth, K. Kraywinkel, M. Wagner, O. Busse, R. L. Haberl, and H.-C. Diener Assessment of Functioning and Disability After Ischemic Stroke Stroke, August 1, 2002; 33(8): 2053 - 2059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Lyden, P. Bath, M. Fisher, and B. C. Tilley Systematic Review of Nimodipine Systematic Review of Nimodipine: Re: Stroke Therapy Academic Industry Roundtable II (STAIR-II) : Re: Stroke Therapy Academic Industry Roundtable II (STAIR-II) Stroke, February 1, 2002; 33(2): 639 - 640. [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Patel, S. R. Levine, B. C. Tilley, J. C. Grotta, M. Lu, M. Frankel, E. C. Haley Jr, T. G. Brott, J. P. Broderick, S. Horowitz, et al. Lack of Clinical Significance of Early Ischemic Changes on Computed Tomography in Acute Stroke JAMA, December 12, 2001; 286(22): 2830 - 2838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Recommendations for Clinical Trial Evaluation of Acute Stroke Therapies Stroke, July 1, 2001; 32(7): 1598 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Lyden, M. Lu, S. R. Levine, T. G. Brott, J. Broderick, and R. Cote A Modified National Institutes of Health Stroke Scale for Use in Stroke Clinical Trials : Preliminary Reliability and Validity Editorial Comment : The NIH Stroke Scale: Is Simpler Better? Stroke, June 1, 2001; 32(6): 1310 - 1317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Marler, B. C. Tilley, M. Lu, T. G. Brott, P. C. Lyden, J. C. Grotta, J. P. Broderick, S. R. Levine, M. P. Frankel, S. H. Horowitz, et al. Early stroke treatment associated with better outcome: The NINDS rt-PA Stroke Study Neurology, December 12, 2000; 55(11): 1649 - 1655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Broderick, M. Lu, R. Kothari, S. R. Levine, P. D. Lyden, E. C. Haley, T. G. Brott, J. Grotta, B. C. Tilley, J. R. Marler, et al. Finding the Most Powerful Measures of the Effectiveness of Tissue Plasminogen Activator in the NINDS tPA Stroke Trial Stroke, October 1, 2000; 31(10): 2335 - 2341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Kwiatkowski, R. B. Libman, M. Frankel, B. C. Tilley, L. B. Morgenstern, M. Lu, J. P. Broderick, C. A. Lewandowski, J. R. Marler, S. R. Levine, et al. Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year N. Engl. J. Med., June 10, 1999; 340(23): 1781 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Hacke, E. Bluhmki, T. Steiner, T. Tatlisumak, M.-H. Mahagne, M.-L. Sacchetti, and D. Meier Dichotomized Efficacy End Points and Global End-Point Analysis Applied to the ECASS Intention-to-Treat Data Set : Post Hoc Analysis of ECASS I Stroke, October 1, 1998; 29(10): 2073 - 2075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Brott, M. Lu, R. Kothari, S. C. Fagan, M. Frankel, J. C. Grotta, J. Broderick, T. Kwiatkowski, C. Lewandowski, E. C. Haley Jr, et al. Hypertension and Its Treatment in the NINDS rt-PA Stroke Trial Stroke, August 1, 1998; 29(8): 1504 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. N. t-P. S. S. Group Generalized Efficacy of t-PA for Acute Stroke : Subgroup Analysis of the NINDS t-PA Stroke Trial Stroke, November 1, 1997; 28(11): 2119 - 2125. [Abstract] [Full Text]
|
|